Etravirine
Generic Name: etravirine
Brand Names:
Etravirine
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) available in tablet form (25 mg, 100 mg, and 200 mg) with white to off-white coloring.
Overview
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) available in tablet form (25 mg, 100 mg, and 200 mg) with white to off-white coloring.
Uses
Treatment of HIV-1 infection in antiretroviral treatment-experienced adult and pediatric patients aged 2 years and older, used in combination with other antiretroviral agents.
Dosage
Adults: 200 mg twice daily following a meal. Pediatric dosing based on body weight (10-20 kg: 100 mg twice daily; 20-25 kg: 125 mg twice daily; 25-30 kg: 150 mg twice daily; 30 kg and above: 200 mg twice daily). Tablets should be swallowed whole or dispersed in water.
Side Effects
Most common: rash (10%) and peripheral neuropathy (4%) in adults. Severe reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome.
Interactions
Significant interactions with NNRTIs, protease inhibitors, and CYP450 inducers/inhibitors. Co-administration with other NNRTIs is not recommended. Dose adjustments may be necessary with multiple drug classes.
Warnings
Severe, potentially fatal skin reactions reported including Stevens-Johnson syndrome and toxic epidermal necrolysis. Immediate discontinuation recommended if severe hypersensitivity develops. Monitor for immune reconstitution syndrome and fat redistribution.
Pregnancy
Limited data in pregnancy. Animal studies showed no adverse effects. Same dosing (200 mg twice daily) recommended during pregnancy. Breastfeeding is not recommended due to potential for HIV-1 transmission.
Frequently Asked Questions
What is Etravirine used for?▼
Treatment of HIV-1 infection in antiretroviral treatment-experienced adult and pediatric patients aged 2 years and older, used in combination with other antiretroviral agents.
What are the side effects of Etravirine?▼
Most common: rash (10%) and peripheral neuropathy (4%) in adults. Severe reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome.
Can I take Etravirine during pregnancy?▼
Limited data in pregnancy. Animal studies showed no adverse effects. Same dosing (200 mg twice daily) recommended during pregnancy. Breastfeeding is not recommended due to potential for HIV-1 transmission.
What are the important warnings for Etravirine?▼
Severe, potentially fatal skin reactions reported including Stevens-Johnson syndrome and toxic epidermal necrolysis. Immediate discontinuation recommended if severe hypersensitivity develops. Monitor for immune reconstitution syndrome and fat redistribution.
Related Medications
Leodopa
leodopa
Manufactured by ZYDUS PHARMS USA INC. Dosage form: CAPSULE, EXTENDED RELEASE. Active ingredients: CARBIDOPA (36.25MG); LEODOPA. Application: ANDA210911.
Rimegepant
rimegepant
Dosage form: POWDER. Active ingredients: RIMEGEPANT (1 kg/1). Category: DRUG FOR FURTHER PROCESSING.
Adalimumab-atto
adalimumab-atto
Tumor Necrosis Factor Blocker [EPC]
11 DESCRIPTION Adalimumab-atto is a tumor necrosis factor blocker. Adalimumab-atto is a recombinant human IgG1 monoclonal antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab-atto is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary (CHO)) expression system and is purified by a process that includes specific viral inactivation and removal steps.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.